Clinical and Translational Oncology

, Volume 20, Issue 4, pp 476–483 | Cite as

Usefulness of lymphocyte-to-monocyte, neutrophil-to-monocyte and neutrophil-to-lymphocyte ratios as prognostic markers in breast cancer patients treated with neoadjuvant chemotherapy

  • C. Marín Hernández
  • A. Piñero Madrona
  • P. J. Gil Vázquez
  • P. J. Galindo Fernández
  • G. Ruiz Merino
  • J. L. Alonso Romero
  • P. Parrilla Paricio
Research Article

Abstract

Background

Nowadays, neoadjuvant chemotherapy (nCT) in breast cancer is more and more standardized, not only in advanced tumours but also in those for which there is an attempt to achieve breast-conserving surgery. In literature, we can find evidences of the relationship between several types of tumours and systemic inflammatory response. Our objective is to analyse the prognostic value of blood parameters (lymphocytes, neutrophils, monocytes, lymphocyte-to-monocyte ratio (LMR), neutrophil-to-monocyte ratio (NMR) and neutrophil-to-lymphocyte ratio (NLR) in breast cancer (BC) patients treated with nCT.

Methods

A retrospective cohort of 150 breast cancer patients treated with nCT and subsequently with surgery was analysed. Data about the patients, histology, response to chemotherapy and peripheral blood values of lymphocytes, monocytes and neutrophils was collected, and used to calculate the LMR, NMR and NLR. Univariate and multivariate analyses were performed for the variables to see the relationship of the ratios to disease-free survival (DFS) and overall survival (OS).

Results

Patients with high LMR (≥5.46) and low NLR (<3.33) were associated with a lower percentage of relapse (P = 0.048 and P = 0.015, respectively) and, above all, NLR was associated with a better survival (P = 0.024), being those factors that predict a good progress.

Conclusion

High LMR and low NLR can be considered as favourable prognostic factors in BC patients treated with nCT.

Keywords

Neoadjuvant chemotherapy Breast cancer Lymphocyte-to-monocyte ratio Neutrophil-to-lymphocyte ratio Neutrophil-to-monocyte ratio 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

All patients signed informed consent prior to treatment. All of them were informed and in accordance with medical practise.

References

  1. 1.
    Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66(4):271–89.CrossRefPubMedGoogle Scholar
  2. 2.
    Mieog JS, Van der Hage JA, Van de Velde CJ. Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev. 2007;18;(2):CD005002 (review).Google Scholar
  3. 3.
    Prabhudesai SR, Malini AV, Raghavendra RM, Ashwini NR, Geetha VP, Patil S, et al. Pathologic complete response rates following neoadjuvant chemotherapy in the treatment of locally advanced breast cancer. In: ASCO annual meeting proceedings, vol 29, no. 15 suppl. 2011.Google Scholar
  4. 4.
    Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883–99.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Roxburgh CS, McMillan DC. Review role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol. 2010;6(1):149–63.CrossRefPubMedGoogle Scholar
  6. 6.
    Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–7.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Krenn-Pilko S, Langsenlehner U, Thurner EM, Stojakovic T, Pichler M, Gerger A, et al. The elevated preoperative platelet-to-lymphocyte ratio predicts poor prognosis in breast cancer patients. Br J Cancer. 2014;110(10):2524–30.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Engin H, Bilir C, Tekin IO. Prognostic significance of peripheral blood flow cytometry parameters in patients with non-metastatic breast cancer. Asian Pac J Cancer Prev. 2013;14:7645–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Tang X. Tumor-associated macrophages as potential diagnostic and prognostic biomarkers in breast cancer. Cancer Lett. 2013;332:3–10.CrossRefPubMedGoogle Scholar
  10. 10.
    Kwon HC, Kim SH, Oh SY, Lee S, Lee JH, Choi HJ, et al. Clinical significance of preoperative neutrophil-lymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer. Biomarkers. 2012;17(3):216–22.CrossRefPubMedGoogle Scholar
  11. 11.
    Domagala-Kulawik J. The role of the immune system in non-small cell lung carcinoma and potential for therapeutic intervention. Transl Lung Cancer Res. 2015;4:177–90.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Sun D, Elson P, Liedtke M, Medeiros BC, Earl M, Alizadeh A, et al. Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemia. Am J Hematol. 2012;87:957–60.CrossRefPubMedGoogle Scholar
  13. 13.
    Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ, et al. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22(8):1736–47.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Ogston KN, Miller ID, Payne S, Hutcheon AW, Sarkar TK, Smith I. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast. 2003;12:320–7.CrossRefPubMedGoogle Scholar
  15. 15.
    Cortazar P, Zhang L, Untch M, Mehta K, Constantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164–72.CrossRefPubMedGoogle Scholar
  16. 16.
    Boughey JC, McCall LM, Ballman KV, Mittendorf EA, Ahrendt GM, Wilke LG, et al. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) prospective multicenter clinical trial. Ann Surg. 2014;260:608–14.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Malyguine AM, Strobl SL, Shurin MR. Immunological monitoring of the tumor immunoenvironment for clinical trials Cancer Immunology. Immunotherapy. 2012;61(2):239–47.CrossRefGoogle Scholar
  18. 18.
    Donskov F. Immunomonitoring and prognostic relevance of neutrophils in clinical trials. Semin Cancer Biol. 2013;23:200–7.CrossRefPubMedGoogle Scholar
  19. 19.
    Aggarwal B, Gehlot P. Inflammation and cancer: how friendly is the relationship for cancer patients? Curr Opin Pharmacol. 2009;9:351–69.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Pierce BL, Ballard-Barbash R, Berstein L, Baumgartner RN, Ml Neuhouser, Wener MH, et al. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol. 2009;21:3437–44.CrossRefGoogle Scholar
  21. 21.
    Proctor M, Morrison D, Talwar D, Balmer SM, Fletcher CD, O´Reilly DJ, et al. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow inflammation outcome study. Eur J Cancer. 2011;47:2633–41.CrossRefPubMedGoogle Scholar
  22. 22.
    Xiao-Jian N, Xiao-Lan Z, Qian-Wen OY, Guo-Wei Q, Lei W, Sheng C, et al. An elevated peripheral blood lymphocyte-to-monocyte ratio predicts favorable response and prognosis in locally advanced breast cancer following neoadjuvant chemotherapy. PLoS One. 2014;9(11):e111886.CrossRefGoogle Scholar
  23. 23.
    Zhang GM, Zhu Y, Luo L, Wan FN, Zhu YP, Sun LJ, et al. Preoperative lymphocyte-monocyte and platelet-lymphocyte ratios as predictors of overall survival in patients with bladder cancer undergoing radical cystectomy. Tumor Biol. 2015;36(11):8537–43.CrossRefGoogle Scholar
  24. 24.
    Azab B, Shah N, Radbel J, Tan P, Bhatt V, Vonfrolio S, et al. Pretreatment neutrophil/lymphocyte ratio is superior to platelet/lymphocyte ratio as a predictor of long-term mortality in breast cancer patients. Med Oncol. 2013;30:432.CrossRefPubMedGoogle Scholar
  25. 25.
    Pusztai L, Mendoza TR, Reuben JM, Martinez MM, Willey JS, Lara J, et al. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine. 2004;2004(25):94–102.CrossRefGoogle Scholar
  26. 26.
    Gorelik E, Landsittel DP, Marrangoni AM, Modugno F, Velikokhatnaya L, Matthew T, et al. Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol Biomark Prev. 2005;14:981–7.CrossRefGoogle Scholar
  27. 27.
    Yao M, Liu Y, Jin H, Liu X, Lv K, Wei H, et al. Prognostic value of preoperative inflammatory markers in Chinese patients with breast cancer. OncoTargets Ther. 2014;7:1743–52.Google Scholar
  28. 28.
    Retsky M, Rogers R, Demicheli R, Hrushesky JM, Gukas I, Vaidya JS, et al. NSAID analgesic ketorolac used perioperatively may suppress early breast cancer relapse: particular relevance to triple negative subgroup. Breast Cancer Res Treat. 2012;134:881.CrossRefPubMedGoogle Scholar
  29. 29.
    Bergamaschi A, Tagliabue E, Sørlie T, Naume B, Triulzi T, Orlandi R, et al. extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. J Pathol. 2008;214(3):357–67.CrossRefPubMedGoogle Scholar
  30. 30.
    Andre F, Berrada N, Desmedt C. implication of tumor microenvironment in the resistance to chemotherapy in breast cancer patients. Curr Opin Oncol. 2010;22(6):547–51.CrossRefPubMedGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2017

Authors and Affiliations

  1. 1.Breast Unit, Service of General SurgeryUniversity Hospital Virgen de la ArrixacaMurciaSpain
  2. 2.Department of SurgeryUniversity Hospital Virgen de la ArrixacaMurciaSpain

Personalised recommendations